Free Trial
NASDAQ:OKUR

OnKure Therapeutics (OKUR) Stock Price, News & Analysis

OnKure Therapeutics logo
$3.04 +0.05 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$3.03 -0.01 (-0.33%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About OnKure Therapeutics Stock (NASDAQ:OKUR)

Advanced

Key Stats

Today's Range
$2.91
$3.15
50-Day Range
$2.00
$2.99
52-Week Range
$1.70
$19.40
Volume
185,021 shs
Average Volume
106,496 shs
Market Capitalization
$41.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.33
Consensus Rating
Moderate Buy

Company Overview

OnKure Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

OKUR MarketRank™: 

OnKure Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 304th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OnKure Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    OnKure Therapeutics has a consensus price target of $32.33, representing about 981.0% upside from its current price of $2.99.

  • Amount of Analyst Coverage

    OnKure Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about OnKure Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OnKure Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OnKure Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OnKure Therapeutics has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OnKure Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.41% of the float of OnKure Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    OnKure Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OnKure Therapeutics has recently decreased by 2.37%, indicating that investor sentiment is improving.
  • Dividend Yield

    OnKure Therapeutics does not currently pay a dividend.

  • Dividend Growth

    OnKure Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.41% of the float of OnKure Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    OnKure Therapeutics has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in OnKure Therapeutics has recently decreased by 2.37%, indicating that investor sentiment is improving.
  • Search Interest

    4 people have searched for OKUR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,024.00 in company stock.

  • Percentage Held by Insiders

    17.90% of the stock of OnKure Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OnKure Therapeutics' insider trading history.
Receive OKUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OKUR Stock News Headlines

Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
OKUR OnKure Therapeutics, Inc.
See More Headlines

OKUR Stock Analysis - Frequently Asked Questions

OnKure Therapeutics' stock was trading at $8.60 at the beginning of the year. Since then, OKUR shares have decreased by 65.2% and is now trading at $2.9910.

OnKure Therapeutics, Inc. (NASDAQ:OKUR) announced its quarterly earnings data on Tuesday, August, 12th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.23) by $0.09.

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/12/2025
Today
10/08/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OKUR
Previous Symbol
NASDAQ:OKUR
CIK
1637715
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$34.00
Low Price Target
$30.00
Potential Upside/Downside
+981.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($4.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$52.67 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-60.52%
Return on Assets
-55.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.13
Quick Ratio
11.13

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.78 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
13,530,000
Free Float
11,108,000
Market Cap
$40.47 million
Optionable
N/A
Beta
0.43
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:OKUR) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners